

Joslyn Kirby

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5621870/publications.pdf>

Version: 2024-02-01

71
papers

2,122
citations

331670

21
h-index

254184

43
g-index

72
all docs

72
docs citations

72
times ranked

1463
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes of pregnancy and childbirth in women with hidradenitis suppurativa. Journal of the American Academy of Dermatology, 2022, 86, 61-67.	1.2	3
2	Use of thermal imaging and a dedicated woundâ€imaging smartphone app as an adjunct to staging hidradenitis suppurativa. British Journal of Dermatology, 2022, 186, 723-726.	1.5	5
3	Disease Evaluation and Outcome Measures. , 2022, , 121-129.		0
4	Identification of Biomarkers and Critical Evaluation of Biomarker Validation in Hidradenitis Suppurativa. JAMA Dermatology, 2022, 158, 300.	4.1	33
5	Janus kinase 1 inhibitor <sc>INCB054707</sc> for patients with moderateâ€toâ€severe hidradenitis suppurativa: results from two phase <sc>II</sc> studies*. British Journal of Dermatology, 2022, 186, 803-813.	1.5	44
6	Evaluation of a Case Series of Patients With Palmoplantar Pustulosis in the United States. JAMA Dermatology, 2022, 158, 68.	4.1	11
7	Damage in Hidradenitis Suppurativa: A Narrative Review Emphasizing the Need for a Novel Outcome Measure. British Journal of Dermatology, 2022, , .	1.5	1
8	Internalized skin bias: validation study to explore the impact of the internalization of social stigma on those with hidradenitis suppurativa. Journal of the European Academy of Dermatology and Venereology, 2022, , .	2.4	4
9	Associations of Internalized Skin Bias With Age, Adverse Psychopathology, and Health-Related Quality of Life Among Patients With Hidradenitis Suppurativa. JAMA Dermatology, 2022, 158, 432.	4.1	3
10	International consensus definition of disease flare in hidradenitis suppurativa. British Journal of Dermatology, 2022, 187, 785-787.	1.5	6
11	Development and initial validation of the <sc>HSâ€IGA</sc> : a novel hidradenitis suppurativaâ€specific investigator global assessment for use in interventional trials*. British Journal of Dermatology, 2022, 187, 203-210.	1.5	8
12	Validation of global item for assessing impact on quality of life of patients with hidradenitis suppurativa*. British Journal of Dermatology, 2021, 184, 681-687.	1.5	15
13	Cross-sectional study reveals reduced odds of allergies in people with hidradenitis suppurativa. Journal of the American Academy of Dermatology, 2021, 85, 232-234.	1.2	3
14	Characterizing physical symptoms of flare in hidradenitis suppurativa: a patient survey. British Journal of Dermatology, 2021, 184, 160-162.	1.5	0
15	Unraveling the Heterogeneity of Hidradenitis Suppurativa with Phenotype Schema. Journal of Investigative Dermatology, 2021, 141, 1136-1138.	0.7	6
16	Hidradenitis Suppurativa Area and Severity Index Revised (HASIâ€R): psychometric property assessment*. British Journal of Dermatology, 2021, 184, 905-912.	1.5	18
17	Convergent Validity of Suffering and Quality of Life as Measured by The Hidradenitis Suppurativa Quality of Life. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1577-1581.	2.4	4
18	Recognizing the Effects and Disparities of Pediatric Hidradenitis Suppurativa. JAMA Dermatology, 2021, 157, 379.	4.1	6

#	ARTICLE	IF	CITATIONS
19	Psychosocial impact of hidradenitis suppurativa: a practical guide for clinicians. <i>Journal of Dermatological Treatment</i> , 2021, , 1-8.	2.2	4
20	Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa. <i>JAMA Surgery</i> , 2021, 156, 1001.	4.3	62
21	Differences Between Children and Adults With Hidradenitis Suppurativa. <i>JAMA Dermatology</i> , 2021, 157, 1095.	4.1	18
22	Hidradenitis Suppurativa Quality of Life (HiSQOL): creation and validation of the Polish language version. <i>Postepy Dermatologii i Alergologii</i> , 2021, 38, 967-972.	0.9	6
23	Efficacy of pediatric dermatology Extension for Community Healthcare Outcomes (ECHO) sessions on augmenting primary care providers' confidence and abilities. <i>Pediatric Dermatology</i> , 2021, , .	0.9	2
24	Periodic worsening, or flare, in hidradenitis suppurativa: the perspective of people with hidradenitis. <i>British Journal of Dermatology</i> , 2020, 182, 218-219.	1.5	11
25	A narrative review of the definition of "flare"™ in hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2020, 182, 24-28.	1.5	6
26	Severity and Area Score for Hidradenitis (<scp>SASH</scp>): a novel outcome measurement for hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2020, 182, 940-948.	1.5	18
27	Support group utilization and impact for patients with hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 216-219.	1.2	15
28	Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 366-376.	1.2	165
29	Loss of Skin Microbial Diversity and Alteration of Bacterial Metabolic Function in Hidradenitis Suppurativa. <i>Journal of Investigative Dermatology</i> , 2020, 140, 716-720.	0.7	32
30	Information framing effects on patients' decisions about dysplastic nevus management. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1011-1013.	1.2	2
31	Prevalence and Impact of Dietary Avoidance among Individuals with Hidradenitis Suppurativa. <i>Dermatology</i> , 2020, 236, 289-295.	2.1	12
32	The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials. <i>British Journal of Dermatology</i> , 2020, 183, 340-348.	1.5	52
33	Standing up together to the shame and stigma associated with hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2020, 182, 267-268.	1.5	6
34	What causes hidradenitis suppurativa "15 years after. <i>Experimental Dermatology</i> , 2020, 29, 1154-1170.	2.9	90
35	Response to Ring et al.: In Silico Predictive Metagenomic Analyses Highlight Key Metabolic Pathways Impacted in the Hidradenitis Suppurativa Skin Microbiome. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1476-1479.	0.7	1
36	Defining lesional, perilesional and unaffected skin in hidradenitis suppurativa: proposed recommendations for clinical trials and translational research studies. <i>British Journal of Dermatology</i> , 2019, 181, 1339-1341.	1.5	28

#	ARTICLE	IF	CITATIONS
37	Increased risk of alopecia areata for people with hidradenitis suppurativa in a cross-sectional study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1431-1432.	1.2	7
38	North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 91-101.	1.2	206
39	E-cadherin and p120ctn protein expression are lost in hidradenitis suppurativa lesions. <i>Experimental Dermatology</i> , 2019, 28, 867-871.	2.9	9
40	North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 76-90.	1.2	218
41	The associations of depression and coping methods on health-related quality of life for those with hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1137-1139.	1.2	10
42	Bundled payment for actinic keratosis management: Pilot evaluation of developed models. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 679-684.	1.2	0
43	Dermatologists and Antibiotics—Reflecting on Our Habits, the Evidence, and Next Steps. <i>JAMA Dermatology</i> , 2019, 155, 286.	4.1	1
44	Positron emission tomography costs less to patients than conventional screening for malignancy in dermatomyositis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 140-144.	3.4	15
45	The effect of antimicrobial washes on antibacterial resistance in hidradenitis suppurativa lesions. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 821-822.	1.2	5
46	Dose, duration, and cost: opportunities to improve use of long-term oral antibiotics for people with rosacea. <i>Journal of Dermatological Treatment</i> , 2019, 30, 63-67.	2.2	0
47	A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process. <i>British Journal of Dermatology</i> , 2018, 179, 642-650.	1.5	119
48	Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II. <i>British Journal of Dermatology</i> , 2018, 178, 715-721.	1.5	33
49	Protocol for the development of a core domain set for hidradenitis suppurativa trial outcomes. <i>BMJ Open</i> , 2017, 7, e014733.	1.9	37
50	Variation in the Cost of Managing Actinic Keratosis. <i>JAMA Dermatology</i> , 2017, 153, 264.	4.1	15
51	Sex- and Age-Adjusted Population Analysis of Prevalence Estimates for Hidradenitis Suppurativa in the United States. <i>JAMA Dermatology</i> , 2017, 153, 760.	4.1	258
52	Association of Resilience With Depression and Health-Related Quality of Life for Patients With Hidradenitis Suppurativa. <i>JAMA Dermatology</i> , 2017, 153, 1263.	4.1	59
53	Development of a Quality-of-Life Measure for Hidradenitis Suppurativa. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 152-155.	1.2	35
54	Exploring Coping Strategies for Patients With Hidradenitis Suppurativa. <i>JAMA Dermatology</i> , 2016, 152, 1166.	4.1	15

#	ARTICLE	IF	CITATIONS
55	Bundled Payment Models for Actinic Keratosis Management. JAMA Dermatology, 2016, 152, 789.	4.1	16
56	Qualitative study shows disease damage matters to patients with hidradenitis suppurativa. Journal of the American Academy of Dermatology, 2016, 74, 1269-1270.	1.2	13
57	Practitioner research and formative assessment. Clinical Teacher, 2016, 13, 28-32.	0.8	0
58	Workplace formative assessment: faculty members' beliefs. Clinical Teacher, 2016, 13, 33-37.	0.8	4
59	Actinic Keratosis Clinical Practice Guidelines: An Appraisal of Quality. Dermatology Research and Practice, 2015, 2015, 1-7.	0.8	19
60	Duration of oral antibiotic therapy for the treatment of adult acne: A retrospective analysis investigating adherence to guideline recommendations and opportunities for cost-savings. Journal of the American Academy of Dermatology, 2015, 72, 822-827.	1.2	28
61	Increased utilization of emergency department and inpatient care by patients with hidradenitis suppurativa. Journal of the American Academy of Dermatology, 2015, 73, 609-614.	1.2	46
62	Reply: Injectable products considered "samples". Journal of the American Academy of Dermatology, 2015, 72, 198-199.	1.2	0
63	Summertime scorcher: assessing and promoting sunscreen protection in an amusement park setting. Photodermatology Photoimmunology and Photomedicine, 2014, 30, 195-201.	1.5	1
64	Health Care Utilization Patterns and Costs for Patients With Hidradenitis Suppurativa. JAMA Dermatology, 2014, 150, 937.	4.1	87
65	The use of donated products to train residents to perform injectable cosmetic procedures. Journal of the American Academy of Dermatology, 2014, 71, 382-385.	1.2	2
66	A retrospective analysis of the duration of oral antibiotic therapy for the treatment of acne among adolescents: Investigating practice gaps and potential cost-savings. Journal of the American Academy of Dermatology, 2014, 71, 70-76.	1.2	43
67	A survey of dermatology resident education in cosmetic procedures. Journal of the American Academy of Dermatology, 2013, 68, e23-e28.	1.2	23
68	Trichoblastic Carcinoma Associated with Multiple Familial Trichoepithelioma. Dermatologic Surgery, 2012, 38, 2018-2021.	0.8	10
69	Intralesional chemotherapy for nonmelanoma skin cancer: A practical review. Journal of the American Academy of Dermatology, 2010, 63, 689-702.	1.2	87
70	Therapy of Bazooka syndrome. Expert Review of Dermatology, 2009, 4, 567-579.	0.3	0
71	Future directions in hidradenitis suppurativa. Dermatological Reviews, 0, , .	0.5	1